Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corp. achieved a new 52-week high of USD 18.18 on June 15, 2026, despite a challenging year with a 43.03% decline in stock performance. The company has a market capitalization of USD 762 million and notable financial metrics, including a P/E ratio of 7.00.

Integra LifeSciences Holdings Corp. achieved a new 52-week high of USD 18.02 on June 9, 2026, despite facing a challenging year with a 41.6% decline in performance. The company has a market capitalization of USD 762 million and notable financial metrics, including a P/E ratio of 7.00.

Integra LifeSciences Holdings Corp. has achieved a new 52-week high of USD 17.79, despite facing a challenging year with a 44.57% decline in performance. The company, with a market capitalization of USD 762 million, has a P/E ratio of 7.00 and a return on equity of 10.43%.

Integra LifeSciences Holdings Corp. has achieved a new 52-week high of USD 16.70, recovering from a previous low of USD 8.71. However, the company's one-year performance remains significantly negative compared to the S&P 500, indicating ongoing challenges in the pharmaceutical and biotechnology sector.

Integra LifeSciences Holdings Corp. saw a notable increase in stock performance today, reaching an intraday high. Over the past month, the company has demonstrated significant growth, although it has faced challenges in long-term profitability. Its market capitalization is USD 746 million, with various financial metrics indicating mixed performance.

Integra LifeSciences Holdings Corp. achieved a new 52-week high of USD 16.62 on May 28, 2026, despite a challenging year with a 46.3% decline in stock performance. The company has a market capitalization of USD 746 million and notable financial metrics, including a P/E ratio of 6.00.

Integra LifeSciences Holdings Corp. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company, with a market capitalization of approximately USD 1,011 million, faces challenges indicated by negative trends in operating profit and cash flow, raising concerns about its future performance.

Integra LifeSciences Holdings Corp. has recently faced significant challenges in its stock performance, with notable declines over the past year and three years. Despite a modest monthly gain, the company's year-to-date results remain unfavorable compared to the S&P 500, reflecting ongoing market difficulties and bearish technical indicators.

Integra LifeSciences Holdings Corp. opened with a notable loss, reflecting a decline over the past day and month. The company's financial metrics include a market capitalization of around USD 1,011 million, a price-to-earnings ratio of 9.00, and a debt-to-equity ratio of 1.52, with no dividend yield.

Integra LifeSciences Holdings Corp. has faced significant stock volatility, with a notable decline in performance over various timeframes, including a year-to-date drop of nearly 48%. The company is grappling with operational challenges, reflected in reduced cash flow and diminishing stakeholder confidence, amid ongoing struggles in the pharmaceuticals and biotechnology sector.

Integra LifeSciences Holdings Corp. has hit a new 52-week low, reflecting a challenging year with a significant stock price decline. The company faces difficulties in growth, evidenced by negative operating profit growth and low operating cash flow. Promoter confidence is also waning, indicating ongoing financial challenges.

Integra LifeSciences Holdings Corp. has experienced notable stock fluctuations, with a recent closing price of $14.80. The company faces mixed technical signals and has underperformed compared to the S&P 500, showing significant declines over the past year and year-to-date, indicating challenges in aligning with market trends.